Clinical research study
Risk Factors for Heart Failure: A Population-Based Case-Control Study

https://doi.org/10.1016/j.amjmed.2009.04.022Get rights and content

Abstract

Background

The relative contribution of risk factors to the development of heart failure remains controversial. Further, whether these contributions have changed over time or differ by sex is unclear. Few population-based studies have been performed. We aimed to estimate the population attributable risk (PAR) associated with key risk factors for heart failure in the community.

Methods

Between 1979 and 2002, 962 incident heart failure cases in Olmsted County were age and sex-matched to population-based controls using Rochester Epidemiology Project resources. We determined the frequency of risk factors (coronary heart disease, hypertension, diabetes mellitus, obesity, and smoking), odds ratios, and PAR of each risk factor for heart failure.

Results

The mean number of risk factors for heart failure per case was 1.9 ± 1.1 and increased over time (P <.001). Hypertension was the most common (66%), followed by smoking (51%). The prevalence of hypertension, obesity, and smoking increased over time. The risk of heart failure was particularly high for coronary disease and diabetes with odds ratios (95% confidence intervals) of 3.05 (2.36-3.95) and 2.65 (1.98-3.54), respectively. However, the PAR was highest for coronary disease and hypertension; each accounted for 20% of heart failure cases in the population, although coronary disease accounted for the greatest proportion of cases in men (PAR 23%) and hypertension was of greatest importance in women (PAR 28%).

Conclusion

Preventing coronary disease and hypertension will have the greatest population impact in preventing heart failure. Sex-targeted prevention strategies might confer additional benefit. However, these relationships can change, underscoring the importance of continued surveillance of heart failure.

Section snippets

Study Population

Olmsted County, Minnesota, has an estimated population of 137,521 (2006 US Census); 50.4% are female. Epidemiologic research is possible because the county is isolated from other urban centers, and medical care is delivered to local residents by few providers.8 Through the Rochester Epidemiology Project, the medical records from all sources of care used by the population are linked, providing a unique infrastructure to analyze disease determinants and outcomes. This study was approved by the

Study Population

The study included 962 subjects with heart failure (mean age of cases 75.4 years; 53.7% were women). Women were older than men (mean age 78.3 years vs 72.1 years, P <.001). By definition, the 962 controls had a similar age and sex distribution.

Frequency of Heart Failure Risk Factors Among Case Subjects

Hypertension was most common, followed by smoking (Table 1). Among ever smokers, 24.0% were light smokers, and 76.0% were heavy smokers. The mean number of heart failure risk factors per case subject was 1.9 ± 1.1; 29.4% had 1 risk factor, 62.0% had 2 or

Discussion

This population-based study indicates that coronary disease, hypertension, diabetes, obesity, and smoking commonly precede the development of heart failure in both men and women. The risk of heart failure is greatest for coronary disease and diabetes, whereas coronary disease and hypertension are responsible for the largest proportion of new heart failure cases in the population. Sex differences in the cause of heart failure might exist, with hypertension playing the greatest role in women and

Limitations

Some limitations should be acknowledged to aid in data interpretation. Rare heart failure risk factors were not explored. Risk factors were ascertained by medical record review, which might lead to under-recognition, but should not differ between cases and controls. Because the study population was mainly white, these data need replication in other racial and ethnic groups. Finally, we used a case-control design, and the associated biases are largely minimized by use of population-based

Conclusions

Although advances in medical therapies have led to improvements in survival after heart failure diagnosis, prognosis remains poor.1, 2, 37 The best strategy for avoidance of morbidity and mortality from heart failure is prevention. The present study has important public health implications and suggests that targeting prevention of hypertension and coronary disease might have the greatest impact on reducing the number of heart failure cases in the population. However, as the relative

References (37)

  • V.L. Roger et al.

    Trends in heart failure incidence and survival in a community-based population

    JAMA

    (2004)
  • J. He et al.

    Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study

    Arch Intern Med

    (2001)
  • D. Levy et al.

    The progression from hypertension to congestive heart failure

    JAMA

    (1996)
  • S. Kenchaiah et al.

    Obesity and the risk of heart failure

    N Engl J Med

    (2002)
  • K.K. Ho et al.

    Survival after the onset of congestive heart failure in Framingham Heart Study subjects

    Circulation

    (1993)
  • M. Khan et al.

    Attributable risk

  • J. Benichou

    Methods of adjustment for estimating the attributable risk in case-control studies: a review

    Stat Med

    (1991)
  • G. Perseghin et al.

    Abnormal left ventricular energy metabolism in obese men with preserved systolic and diastolic functions is associated with insulin resistance

    Diabetes Care

    (2007)
  • Cited by (199)

    • General Population and Global Cardiovascular Risk Prediction

      2023, Hypertension: A Companion to Braunwald's Heart Disease
    View all citing articles on Scopus

    Funding: National Institutes of Health Ruth L. Kirschstein National Research Service Award (T32 HL07111-31A1) to Dr Dunlay. American Heart Association Postdoctoral Fellowship Award to Dr Dunlay. National Institutes of Health RO1 (HL72435) to Dr Roger. This study was made possible by the Rochester Epidemiology Project (Grant #R01-AR30582 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases).

    Conflict of Interest: Dr Jacobsen has received research funding from and served as an unpaid consultant to Merck Research Laboratories, but there is no relationship to the present study.

    Authorship: All authors had access to the data and played a role in writing this manuscript.

    View full text